The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema. Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with diabetic macular edema with fewer treatments based on its continuous delivery of a

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the treatment of diabetic macular edema (DMO). According to the company,

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a one-time, outpatient procedure, continuously delivering a customized formulation of ranibizumab over time.

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already-approved drug to head off the leading cause of blindness in people with diabetes.

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened its label as a treatment for diabetic macular edema (DME), which is the leading cause of diabetes-related blindness.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susv

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with fewer treatments than standard eye injections.